Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)

Trial Profile

Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms PASART-2
  • Most Recent Events

    • 26 Sep 2017 Planned number of patients changed from 50 to 35.
    • 26 Sep 2017 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
    • 26 Sep 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top